Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug;103(8):3135-3143.
doi: 10.1007/s00277-024-05818-5. Epub 2024 May 29.

Reduced-toxicity conditioning regimen with low dose post-transplantation cyclophosphamide and low-dose anti-thymocyte globulin as graft-versus-host disease prophylaxis for haploidentical stem cell transplantation in older patients

Peipei Ye  1   2 , Mengjie Wu  1   2 , Junjie Cao  1   2 , Renzhi Pei  1   2 , Jiaojiao Yuan  1   2 , Haihui Zhuang  1   2 , Ying Fang  1   2 , Ying Lu  3   4
Affiliations

Reduced-toxicity conditioning regimen with low dose post-transplantation cyclophosphamide and low-dose anti-thymocyte globulin as graft-versus-host disease prophylaxis for haploidentical stem cell transplantation in older patients

Peipei Ye et al. Ann Hematol. 2024 Aug.

Abstract

Reduced-toxicity conditioning (RIC) regimens are used for allogeneic hematopoietic stem cell transplantation in older patients. However, successful outcomes are hindered by graft-versus-host disease (GVHD), treatment-related mortality, and relapse, particularly after haploidentical donor hematopoietic stem cell transplantation (HID-HSCT). The aim of this study was to evaluate the effectiveness of an RIC conditioning regimen that included a combination of cyclosporin A, methotrexate (on day + 1), mycophenolate, lower doses of post-transplantation PTCy (40 mg/kg on day + 3), and ATG (7.5 mg/kg) as GVHD prophylaxis prior to haplo-stem cell transplantation (haplo-SCT) in older patients.

Methods: We retrospectively analyzed outcomes in 55 patients ≥ 55 years of age with hematologic malignancies treated with fludarabine, cytarabine, busulfan, and low-dose cyclophosphamide as the conditioning regimen between January 1, 2019, and November 30, 2023.

Results: Neutrophil engraftment was successful in all patients within 28 days, with 54 patients (98.2%) achieving complete donor chimerism. The cumulative incidence of non-relapse mortality was 0% at 30 days, 7.5% at 100 days, and 19% at 1 year. The cumulative incidence of grade II-IV acute graft-versus-host disease (aGVHD) was 25% (95%CI, 15-38%), whereas that of grade III-IV aGVHD was 9.1% (95% CI, 3.3-19%). The cumulative incidence of extensive chronic graft-versus-host disease at 1 year was 3.6% (95%CI, 0.66-11%). The cumulative incidences of relapse, overall survival, and GVHD-free/relapse-free survival at 1 year were 9.0%, 71.6%, and 67.1%, respectively.

Conclusions: An RIC conditioning regimen, including a combination of lower PTCy/ATG as GVHD prophylaxis, followed by haplo-SCT, might be a promising option for appropriately selected older patients.

Keywords: Anti-thymocyte globulin; Haploidentical stem cell transplantation; Older patients; Post-transplantation cyclophosphamide; Reduced-toxicity conditioning regimen.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Ustun C, Le-Rademacher J, Wang HL et al (2019) Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60–75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. Leukemia 33:2599–2609. https://doi.org/10.1038/s41375-019-0477-x - DOI - PubMed - PMC
    1. Kanapuru B, Singh H, Kwitkowski V, Blumenthal G, Farrell AT, Pazdur R (2020) Older adults in hematologic malignancy trials: representation, barriers to participation and strategies for addressing underrepresentation. Blood Rev 43:100670. https://doi.org/10.1016/j.blre.2020.100670 - DOI - PubMed
    1. Ciurea SO, Rodrigues M, Giralt S, de Lima M (2009) Aging, acute myelogenous leukemia, and allogeneic transplantation: do they belong in the same sentence? Clin Lymphoma Myeloma 9:289–297. https://doi.org/10.3816/CLM.2009.n.057 - DOI - PubMed
    1. Kasamon YL, Bolanos-Meade J, Prince GT et al (2015) Outcomes of nonmyeloablative HLA-Haploidentical blood or marrow transplantation with high-dose Post-transplantation Cyclophosphamide in older adults. J Clin Oncol 33:3152–3161. https://doi.org/10.1200/JCO.2014.60.4777 - DOI - PubMed - PMC
    1. Sun YQ, Han TT, Wang Y et al (2021) Haploidentical stem cell transplantation with a Novel Conditioning Regimen in older patients: a prospective single-arm phase 2 study. Front Oncol 11:639502. https://doi.org/10.3389/fonc.2021.639502 - DOI - PubMed - PMC

MeSH terms

LinkOut - more resources